Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.
PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia
- Thread starter Educator
- Start date